New findings from the phase 3 INAVO120 trial underscore the durable benefits of inavolisib added to standard therapy for PIK3CA-mutated hormone receptor–positive (HR+) human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer. The drug, in combination with palbociclib and fulvestrant, was approved in October 2024 by the US Food and Drug Administration based on …
Leave a Comment Leave a Comment
